Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Loading...
Type
Article
Change log
Authors
Abstract
The process of anti-cancer drug development is complex, with high attrition rates. Factors that may optimise this process include well-constructed and relevant pre-clinical testing and use of biomarkers for patient selection. However, the design of early phase clinical trials will probably play a vital role in both the robust clinical investigation of new targeted therapies and in streamlining drug development. In this overview, we assess current concepts in phase I clinical trials, highlighting issues and opportunities to improve their meaningfulness. The particular challenge of how to design combination trials is addressed, with focus on the potential of new adaptive and model-based designs.
Description
Keywords
Adaptive design, biomarker, dose escalation methods, early phase clinical trials, phase I trials, Antineoplastic Agents, Clinical Trials as Topic, Humans, Neoplasms, Research Design
Journal Title
Clin Oncol (R Coll Radiol)
Conference Name
Journal ISSN
0936-6555
1433-2981
1433-2981
Volume Title
29
Publisher
Elsevier BV
Publisher DOI
Rights
All rights reserved